Skinvisible subsidiary Skinvisible Pharmaceuticals has received notice from the United States Patent and Trademark Office that its patent application for "Topical Composition, Topical Composition Precursor, and Methods For Manufacturing And Using" has issued as US Patent Number 6,756,059.
The patent is directed at manufacturing topical polymer-based delivery system compositions and includes disclosure of various "Topical Compositions and Methods for Manufacturing and Using the Compositions."
A divisional application is pending, directed at "Topical Composition and Methods for Using the Composition."
The Las-Vegas headquartered company has registered the name "Invisicare" to identify the fifteen different polymer compositions it has developed to date.
When topically applied, products incorporating Invisicare adhere to the skin's outer layers forming a protective bond that resists both wash-off and perspiration for extended periods of time, while delivering targetted levels of active ingredients to the skin.
Utilising its technologies, the company has developed and tested antibacterial/antimicrobial hand sanitisers, skincare moisturisers, sunscreens, sunless tanners, acne, psoriasis, eczema, tooth whitener and other topical OTC formulations.
Company president Terry Howlett said: "This will greatly assist our customer base of both cosmetic and pharmaceutical companies in offering protection for their proprietary products."
Skinvisible chemist and inventor Dr James Roszell added: "Of significant note is that Invisicare offers distinct advantages for drug delivery over conventional creams and ointments."
The company claimed that Invisicare offered enhanced skin adherence due to sustained drug delivery for longer periods of time.
Skinvisible focuses its activities on the development of innovative topical polymer-based delivery systems and related technologies incorporating its patent-pending formula/process for combining hydrophilic and hydrophobic polymers into stable water emulsions.